Online inquiry

IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10359MR)

This product GTTS-WQ10359MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10359MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13932MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ5182MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ3844MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ12286MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3813MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ10245MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ12365MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ1911MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW